You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives

    SBC: SOLANO PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. In toto Handheld Bioagent Detector by Digital Fluidics

    SBC: Core MicroSolutions, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The design and evaluation of a handheld digital microfluidic (DMF) bioagent analyzer is proposed by Core Microsolutions (CMSS) and University of Michigan Professor K.-D. Lee (College of Pharmacy) for a two year Phase I research period in the NIH Small Business Biodefense Program. This proposed research will integrate: 1) Electrowetting on Dielectric (EWOD) drop ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. A Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging

    SBC: PETcoil, Inc.            Topic: 101

    Project Summary Medical imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have been widely used in studying the underlying mechanisms of mental illnesses and neurological disorders such as brain tumors, Alzheimer’s disease, epilepsy, and depression, etc. However, PET and MRI scans are almost always ordered as separate studies on separate machine ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Broadly Accessible Technologies for Single-cell Joint Analysis of Transcriptome and Epigenome

    SBC: EPIGENOME TECHNOLOGIES, INC            Topic: 101

    AbstractHistone modifications carry rich information of cellular memory and gene regulatory mechanisms. Single cell analysis of histone modification in conjunction with transcriptome could recover this critical layer of cell identity and help to dissect the cellular and molecular composition of complex tissues such as the brain. We recently developed an ultra-high throughput single cell multi-omic ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Generalizing and Standardizing fMRI Tools for Differentiating Mental Illnesses and Predicting Medication-Class Response in Patients

    SBC: ADVANCED BIOMEDICAL INFORMATICS GROUP, L.L.C.            Topic: 102

    Project Summary/AbstractMood disorders, like many psychiatric conditions, have their onset in emerging adulthood and often last a lifetime. Mental illnesses have an excessively large loading of Disability Adjusted Life Years, making early intervention crucial for both individuals and society. Differentiating bipolar disorder (BD) from major depressive disorder (MDD) based on the Diagnostic and Sta ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. A novel approach to restricting the spread of neurofibrillary tau

    SBC: NOVORON BIOSCIENCE INC            Topic: NIA

    7. Project Summary Alzheimer’s disease (AD) is the most common cause of dementia and is a growing problem as populations age. More than 25 million people are affected by dementia worldwide with most suffering from AD. AD is characterized by the presence of plaques of insoluble amyloid-beta (Aβ) and tangles of hyperphosphorylated aggregates of the cytoskeletal protein, tau. Thus far, most AD tre ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government